<DOC>
	<DOCNO>NCT02015533</DOCNO>
	<brief_summary>The purpose study assess safety , pharmacokinetics ( body drug ) immunogenicity ( ability particular substance provoke immune response human body ) CR8020 japanese healthy participant</brief_summary>
	<brief_title>A Study Assess Safety , Pharmacokinetics Immunogenicity CR8020 Japanese Healthy Participants</brief_title>
	<detailed_description>This study randomize ( study medication assign chance ) , double-blind ( neither physician participant know treatment participant receives ) , placebo-controlled ( placebo comparator compare study medication evaluate safety profile study medication clinical study ) , single-dose study Japanese healthy adult male participant . The study include screen phase ( 28 2 day prior study medication administration ) , treatment phase ( Study medication administer Day 1 ) , follow-up phase ( 99 day ) . Twelve participant randomly assign CR8020 50 mg/kg placebo group 2:1 ratio receive assigned treatment Day 1 . Safety assess evaluate adverse event , clinical laboratory test , 12-lead Electrocardiogram , vital sign , physical examination . Total maximum duration participation individual participant 127 day .</detailed_description>
	<criteria>Have sign inform consent document Body mass index 18 30 kg/m2 , body weight great equal 50 kg screening Must agree use adequate contraception method ( eg , vasectomy , doublebarrier , partner use effective contraception ) donate sperm study drug administration Day 99 Blood pressure 90 140 mmHg systolic , inclusive , high 90 mmHg diastolic screen Nonsmoker participant smoke 10 cigarette , 2 cigar , 2 pipe tobacco per day least 6 month study drug administration History current clinically significant medical illness determine investigator include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder Clinically significant abnormal value hematology , clinical chemistry urinalysis Clinically significant abnormal physical examination , vital sign 12lead electrocardiogram A diagnosis influenza infection constellation clinical symptom consistent influenza infection within 14 day study drug administration schedule Participants fever 37.5Â°C Day 1 predose</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Healthy</keyword>
	<keyword>CR8020</keyword>
	<keyword>Japanese</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>